GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » Short Interest

Theriva Biologics (FRA:SFY) Short Interest


View and export this data going back to . Start your Free Trial

What is Theriva Biologics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Theriva Biologics's Short Interest

For the Biotechnology subindustry, Theriva Biologics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theriva Biologics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Short Interest distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Short Interest falls into.


Theriva Biologics (FRA:SFY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » Short Interest
Comparable Companies
ADIL GTBP PRTG FRTX SILO PCSA SONN LIXT AZTR SNPX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TOVX:USA
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Website
https://www.therivabio.com
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics (FRA:SFY) Headlines

From GuruFocus

SOFI WEALTH, LLC Goes on Buying Spree in 2nd Quarter

By GuruFocus Research GuruFocus Editor • 07-25-2022

SoFi Releases SoFi Gig Economy ETF (GIGE) and SoFi 50 ETF (SFYF)

By PRNewswire PRNewswire • 05-08-2019